Theralase Technologies Inc (TLTFF)

[123414]

FEB 7 COPR PREZ BASED OFF NOV 29 2021 DATA
Latest Coprate presentation FEB 7 2022 based of NOV 29 2021 data.

30 patients treated to date in the Phase II NMIBC clinical study
3 patients treated in the
Phase Ib NMIBC clinical
study
Total population of 33
patients patietheralase.com/wp-content/up...nts 5 clinical study sites open in Canada and 7 in United States
Feb 7 2022 copr prez 33 total patients treated (3 from phase one) NO NEW REPORTING FROM 29 NOV 2021!!!
https://theralase.com/wp-content/uploads/2022/02/Corporate-PPT-020722.pdf

Note 32 Theralase® Press Release - Theralase Releases 3Q21 Financial Statements and Newsletter – November 29, 2021 32 Theralase® Press Release -

From the last quarterly newsletter. 3Q2021 | NOVEMBER 2021

Study II Status:
Theralase® has enrolled and treated 30 patients in a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study ("Study II") (including three patients from the Phase Ib NMIBC clinical study (“Study”) treated at the Therapeutic Dose) for a total of 33 patients.
last quarterly newsletter
https://theralase.com/wp-content/uploads/2021/11/3Q-2021-Newsletter.pdf